Autoimmune lymphoproliferative syndrome classification

	Autoimmune lymphoproliferative syndrome Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune lymphoproliferative syndrome classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune lymphoproliferative syndrome classification
CDC on Autoimmune lymphoproliferative syndrome classification
Autoimmune lymphoproliferative syndrome classification in the news
Blogs on Autoimmune lymphoproliferative syndrome classification
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: David Teachey, MD [2] Sharmi Biswas, M.B.B.S

Overview

Classification of ALPS is based on the recommendations made by first international ALPS workshop held at National Institutes of Health in 2009.

The revised classification of ALPS is as following ^[1]
Previous nomenclature	Revised nomenclature	Gene	Definition
ALPStype IIb	CEDS	CASP8	Splenomegaly, marginal raised DNT, recurrent infections, germline mutations in caspase 8
ALPS type IV	RALD	NRAS	Autoimmunity, lymphadenopathy and/or splenomegaly, elevated or normal DNTs, somatic mutations in NRAS
DALD	DALD	Unknown	Lymphadenopathy and /or splenomegaly, autoimmunity, normal DNTs, defective in vitro FAS-mediated apoptosis
XLP1	XLP1	SH2D1A	Hypogammaglobulinemia, fulminant Epstein- Barr virus infection, or lymphoma

↑ Oliveira, Joao B.; Bleesing, Jack J.; Dianzani, Umberto; Fleisher, Thomas A.; Jaffe, Elaine S.; Lenardo, Michael J.; Rieux-Laucat, Frederic; Siegel, Richard M.; Su, Helen C.; Teachey, David T.; Rao, V. Koneti (2010). "Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop". Blood. 116 (14): e35–e40. doi:10.1182/blood-2010-04-280347. ISSN 0006-4971.